"Pulmonary heart disease"

199 resultsPro users have access to +31 Systematic Reviews

Filter Results
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
                    • Pro

                            Clinical Area Pro

                            Further Refinement
                            User Guide

                            User Guide

                            1
                            2024Current Problems in Cardiology
                            Unraveling disparities: Probing gender, race, and geographic inequities in pulmonary heart disease mortality in the United States: An extensive longitudinal examination (1999-2020) leveraging CDC WONDER data. This comprehensive study delves into the epidemiological landscape of Pulmonary Heart Disease (PHD) mortality in the United States from 1999 to 2020, leveraging the extensive CDC WONDER
                            2
                            2024BMC Pulmonary Medicine
                            Significance of serum lncRNA XIST in chronic obstructive pulmonary disease and its progression to pulmonary heart disease. Chronic obstructive pulmonary disease (COPD) has become one of the major death-related causes. Chronic pulmonary heart disease (CPHD) is an adverse complication of COPD causing poor prognosis of patients. This study evaluated the role of lncRNA XIST in COPD and CPHD aiming
                            Subscribe to Trip PRO for an enhanced experience
                            • Access to millions of Full-text articles where avaliable
                            • Unlock 100,000+ extra articles with Systematic Reviews
                            • Further Filtering Options
                            • No adverts
                            • Advanced Search Ability
                            • Enhanced SmartSearch showing unlimited related articles
                            Read more about Trip PRO
                            3
                            "Yiqi Huayu, Wenyang Lishui" Prescription (YHWLP) Improves the Symptoms of Chronic Obstructive Pulmonary Disease-Induced Chronic Pulmonary Heart Disease by Inhibiting the RhoA/ROCK Signaling Pathway. Chronic pulmonary heart disease (CPHD) is a common type of heart disease. In China, chronic obstructive pulmonary disease (COPD) is one of the main causes of CPHD. At present, there is no specific
                            4
                            2024PROSPERO
                            Pre thrombotic state assisted therapy for chronic pulmonary heart disease: A meta-analysis PROSPERO International prospective register of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied
                            5
                            [Multicenter clinical efficacy observation of integrated Traditional Chinese Medicine-Western Medicine treatment in acute onset period of pulmonary heart disease]. To evaluate the efficacy of integrated Traditional Chinese Medicine-Western Medicine (TCM-WM) in the treatment of acute onset pulmonary heart disease (PHD). A total of 240 patients met the inclusion criteria and were enrolled
                            6
                            2016Molecular medicine reports
                            Deciphering the genetic and modular connections between coronary heart disease, idiopathic pulmonary arterial hypertension and pulmonary heart disease Coronary heart disease (CHD), idiopathic pulmonary arterial hypertension (IPAH) and pulmonary heart disease (PHD) are circulatory system diseases that may simultaneously emerge in a patient and they are often treated together in clinical practice
                            7
                            2015American Journal of Cardiology
                            Clinical and morphologic features of acute, subacute and chronic cor pulmonale (pulmonary heart disease). Described are certain clinical and morphologic features of one patient with acute, another with subacute, and one with chronic cor pulmonale. All 3 had evidence of severe pulmonary hypertension. The patient with acute cor pulmonale 4 days after coronary bypass for unstable angina pectoris
                            8
                            2023PROSPERO
                            Resolving phlegm and activating blood, a treatment by traditional Chinese medicine, for Chronic pulmonary heart disease: meta-analysis and network pharmacology PROSPEROInternational prospective register of systematic reviews Print | PDFResolving phlegm and activating blood, a treatment by traditional Chinese medicine, for Chronic pulmonary heart disease: meta-analysis and network registration. Further detail is provided here.Citationtianwei meng, jianying wang, rui qie. Resolving phlegm and activating blood, a treatment by traditional Chinese medicine, for Chronic pulmonary heart disease: meta-analysis and network pharmacology. PROSPERO 2023 CRD42023455567 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023455567Review questionResolving phlegm
                            9
                            2023PROSPERO
                            Network meta-analysis of oral Chinese patent medicine in treatment of pulmonary heart disease PROSPEROInternational prospective register of systematic reviews Print | PDFPROSPEROThis information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied
                            10
                            2023PROSPERO
                            A network meta-analysis of the efficacy and safety of Yiqi traditional Chinese medicine injection in the treatment of chronic pulmonary heart disease PROSPEROInternational prospective register of systematic reviews Print | PDFA network meta-analysis of the efficacy and safety of Yiqi traditional Chinese medicine injection in the treatment of chronic pulmonary heart diseaseHongYi Yue, Senhao PROSPERO registration. Further detail is provided here.CitationHongYi Yue, Senhao Chang, Yimei Li, Pingyi Wang, Ruohao Sun, Wenhua Li. A network meta-analysis of the efficacy and safety of Yiqi traditional Chinese medicine injection in the treatment of chronic pulmonary heart disease. PROSPERO 2023 CRD42023461772 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID
                            11
                            2023PROSPERO
                            Network meta-analysis of traditional Chinese medicine injection in the treatment of chronic pulmonary heart disease PROSPEROInternational prospective register of systematic reviews Print | PDFNetwork meta-analysis of traditional Chinese medicine injection in the treatment of chronic pulmonary heart diseaseban jifang, wang zhuoxiTo enable PROSPERO to focus on COVID-19 submissions of traditional Chinese medicine injection in the treatment of chronic pulmonary heart disease. PROSPERO 2023 CRD42023464762 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023464762Review questionThe purpose of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Chinese medicine injection combined with conventional western medicine
                            12
                            Pulmonary heart disease but not pulmonary embolism admissions peaked at physiologically equivalent temperature 0°C in Germany in 2009-2011.
                            13
                            2022PROSPERO
                            Efficacy and safety of Qili Qiangxin capsule in treatment of pulmonary heart disease : a systematic review and meta-analysis Efficacy and safety of Qili Qiangxin capsule in treatment of pulmonary heart disease : a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith
                            14
                            2022PROSPERO
                            Comparative efficacy of Chinese herbal medicine injections in the treatment of pulmonary heart disease: a systematic review and Bayesian network meta-analysis PROSPEROInternational prospective register of systematic reviews Print | PDFComparative efficacy of Chinese herbal medicine injections in the treatment of pulmonary heart disease: a systematic review and Bayesian network meta -analysisChanghong Miao, Shuoxuan Huang, Xin Sun, Kuang ChenCitationChanghong Miao, Shuoxuan Huang, Xin Sun, Kuang Chen. Comparative efficacy of Chinese herbal medicine injections in the treatment of pulmonary heart disease: a systematic review and Bayesian network meta-analysis. PROSPERO 2022 CRD42022385000 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022385000Review questionTo
                            15
                            2021PROSPERO
                            Treatment of pulmonary heart disease with Zhenwu DecoctionA systematic review protocol Treatment of pulmonary heart disease with Zhenwu DecoctionA systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information
                            16
                            Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease. To explore the effects of atorvastatin on the migration and adhesion of endothelial progenitor cells (EPCs) and on pulmonary artery pressure (PAP) in patients with chronic pulmonary heart disease. A total of 68 patients with chronic pulmonary heart functions of EPCs in the treatment group were greater than in the control group (all P<0.05). The reduction in PAP in the treatment group was greater than in the untreated control group following six months of therapy (P<0.05). Atorvastatin therapy increased the migration and adhesion activities of EPCs in patients with chronic pulmonary heart disease. Atorvastatin treatment was also associated
                            17
                            admissions/need for intubation□ Assessment of persistent symptoms: use of salbutamol, nighttime symptoms, and exercise intolerance □ Presence of complicating illnesses (pulmonary, cardiac)□ Diseases aggravated by steroid therapy (diabetes, hypertension, ulcers, psychosis□ Cigarette smoke exposure (maternal, paternal, caregiver)□ Food allergy/allergies □ Social and environment i.e. crowding in home